Interferon Gamma 1-b

Phase 1Small molecule

AAssistance Publique - Hôpitaux de Paris

Interferon Gamma 1-b is one of 17 small molecule programs targeting Cystoid Macular Edema. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystoid Macular EdemaActive, not recruiting

ImmunosuppressionRecruiting

Cystoid Macular EdemaPhase 1

Active, not recruiting

ImmunosuppressionPreclinical

Recruiting

Competition

Competitive Landscape

23 competitors in Cystoid Macular Edema

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Kenalog

BBausch Health Americas, Inc.

Approved

2 3

Decadron

AAspen Global Incorporated

Approved

2 4

Toradol

JJavelin Pharmaceuticals

Approved

2 5

Ilevro

HHarrow Inc

Approved

2 6

Avastin

Diamox

1 8

Bromday

BBausch Health Americas, Inc.

Phase 2

2 9

Lucentis

Roche

Phase 1

2 10

Macugen

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Prevention

NCT06774235

Q2 2029

PreclinicalRecruiting

Immunosuppression

NCT06694740

Clinical

Trials by Indication[1]

Cystoid Macular Edema1 trial

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

Completed·NNational Eye Institute (NEI)·Phase 1·NCT00943982·5 enrolled

Prevention1 trial

Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression

Recruiting·UUniversity Hospital, Limoges·Phase 3·NCT06774235·326 enrolled

Immunosuppression1 trial

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Recruiting·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT06694740·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Interferon Gamma 1-b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interferon Gamma 1-b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interferon Gamma 1-b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAssistance Publique - Hôpitaux de Paris

Interferon Gamma 1-b

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Cystoid Macular Edema1 trial

Prevention1 trial

Immunosuppression1 trial

References

Drug Info

Quick Facts

Related News